GSA Capital Partners’s Black Diamond Therapeutics BDTX Stock Holding History

GSA Capital Partners’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$409K	Buy	220,907 +51,140	+30%	+$125K	0.03%	1129
2026 Q1	$362K	Sell	169,767 -75,954	-31%	-$181K	0.02%	1129
2025 Q4	$597K	Buy	245,721 +122,963	+100%	+$435K	0.05%	693
2025 Q3	$465K	Sell	122,758 -117,253	-49%	-$343K	0.04%	893
2025 Q2	$595K	Buy	+240,011	New	+$463K	0.04%	800
2024 Q3	–	Sell	-16,814	Closed	-$78K	–	1600
2024 Q2	$78K	Buy	+16,814	New	+$90.3K	0.01%	1545
2022 Q4	–	Sell	-22,486	Closed	-$38K	–	1470
2022 Q3	$38K	Buy	+22,486	New	+$69.3K	0.01%	1436
2021 Q4	–	Sell	-69,299	Closed	-$586K	–	1412
2021 Q3	$586K	Sell	69,299 -3,547	-5%	-$35K	0.06%	605
2021 Q2	$888K	Buy	72,846 +51,646	+244%	+$1.02M	0.1%	307
2021 Q1	$514K	Buy	+21,200	New	+$572K	0.09%	338

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

GSA Capital Partners's BDTX Position: Q2 2026 in Review

GSA Capital Partners increased its Black Diamond Therapeutics (BDTX) stake by 30% in Q2 2026, buying an estimated $125K and bringing the position to 220,907 shares worth $409K. The position accounts for 0.03% of the portfolio, ranked #1129.

GSA Capital Partners first reported a position in BDTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $888K in Q2 2021. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

GSA Capital Partners held 220,907 shares of Black Diamond Therapeutics worth $409K as of Q2 2026.
GSA Capital Partners bought 51,140 Black Diamond Therapeutics shares in Q2 2026, an estimated $125K.
Black Diamond Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #1129 holding.
GSA Capital Partners first reported a position in Black Diamond Therapeutics in Q1 2021 and has held it in 10 quarters since.
GSA Capital Partners's Black Diamond Therapeutics position peaked at $888K in Q2 2021.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.